BACKGROUND: Apolipoprotein A5 (APOA5) gene polymorphisms are usually associated with plasma triglyceride levels. We evaluated the relationship of the APOA5 -1131T>C and c.56C>G polymorphisms [single nucleotide polymorphism (SNP)] with serum lipids, dyslipidemia [low high-density lipoprotein (HDL)/high triglyceride] and the risk for metabolic syndrome (MS) in the Turkish Adult Risk Factor study. METHODS: We genotyped SNPs using the Taqman allelic discrimination assays in 1564 Turkish adults (51.4% female, mean age 54.1+/-11.6 years). MS and dyslipidemia were defined using the criteria of the National Cholesterol Education Program. RESULTS: For both SNPs, rare allele carriers had significantly higher fasting triglyceride levels in both genders, except the c.56G allele in men. The -1131C allele was associated with lower HDL cholesterol (HDL-C) levels in women. In relation to dyslipidemia, the c.56C>G and haplotype 1 had significant gender-genotype interactions (p<0.05). Otherwise, both SNPs were significantly associated with dyslipidemia after adjustment for risk factors in women. After similar adjustment, non-carriers of the haplotype 1 (odds ratio=4.1, p=0.003) increased the MS risk in women. However, no significant associations emerged between SNPs and HDL-C, dyslipidemia or MS in a similar analysis in men. CONCLUSIONS: Excess risk for low HDL-C, dyslipidemia and MS is associated with the rare alleles of the APOA5 SNPs and non-carriers of common haplotype in women.
BACKGROUND:Apolipoprotein A5 (APOA5) gene polymorphisms are usually associated with plasma triglyceride levels. We evaluated the relationship of the APOA5 -1131T>C and c.56C>G polymorphisms [single nucleotide polymorphism (SNP)] with serum lipids, dyslipidemia [low high-density lipoprotein (HDL)/high triglyceride] and the risk for metabolic syndrome (MS) in the Turkish Adult Risk Factor study. METHODS: We genotyped SNPs using the Taqman allelic discrimination assays in 1564 Turkish adults (51.4% female, mean age 54.1+/-11.6 years). MS and dyslipidemia were defined using the criteria of the National Cholesterol Education Program. RESULTS: For both SNPs, rare allele carriers had significantly higher fasting triglyceride levels in both genders, except the c.56G allele in men. The -1131C allele was associated with lower HDL cholesterol (HDL-C) levels in women. In relation to dyslipidemia, the c.56C>G and haplotype 1 had significant gender-genotype interactions (p<0.05). Otherwise, both SNPs were significantly associated with dyslipidemia after adjustment for risk factors in women. After similar adjustment, non-carriers of the haplotype 1 (odds ratio=4.1, p=0.003) increased the MS risk in women. However, no significant associations emerged between SNPs and HDL-C, dyslipidemia or MS in a similar analysis in men. CONCLUSIONS: Excess risk for low HDL-C, dyslipidemia and MS is associated with the rare alleles of the APOA5 SNPs and non-carriers of common haplotype in women.
Authors: Chao Qiang Jiang; Bin Liu; Bernard M Y Cheung; Tai Hing Lam; Jie Ming Lin; Ya Li Jin; Xiao Jun Yue; Kwok Leung Ong; Sidney Tam; Ka Sing Wong; Brian Tomlinson; Karen S L Lam; G Neil Thomas Journal: Eur J Hum Genet Date: 2010-06-23 Impact factor: 4.246
Authors: Ferenc Hadarits; Péter Kisfali; Márton Mohás; Anita Maász; Balázs Duga; Ingrid Janicsek; István Wittmann; Béla Melegh Journal: Mol Biol Rep Date: 2011-06-04 Impact factor: 2.316
Authors: Mary F Feitosa; Ping An; Jose M Ordovas; Shamika Ketkar; Paul N Hopkins; Robert J Straka; Donna K Arnett; Ingrid B Borecki Journal: Atherosclerosis Date: 2011-01-21 Impact factor: 5.162
Authors: Kira C Taylor; Cara L Carty; Logan Dumitrescu; Petra Bůžková; Shelley A Cole; Lucia Hindorff; Fred R Schumacher; Lynne R Wilkens; Ralph V Shohet; P Miguel Quibrera; Karen C Johnson; Brian E Henderson; Jeff Haessler; Nora Franceschini; Charles B Eaton; David J Duggan; Barbara Cochran; Iona Cheng; Chris S Carlson; Kristin Brown-Gentry; Garnet Anderson; Jose Luis Ambite; Christopher Haiman; Loïc Le Marchand; Charles Kooperberg; Dana C Crawford; Steven Buyske; Kari E North; Myriam Fornage Journal: BMC Genet Date: 2013-05-01 Impact factor: 2.797